(Q37142078)

18 August 2017

1 reference

title

Experience with tenofovir disoproxil fumarate for antiretroviral therapy (English)

1 reference

18 August 2017

main subject

anti-retroviral agent

0 references

1 reference

Christoph Stephan

1

1 reference

18 August 2017

language of work or name

English

0 references

publication date

1 May 2008

1 reference

Expert Opinion on Pharmacotherapy

18 August 2017

published in

1 reference

18 August 2017

volume

9

1 reference

18 August 2017

issue

7

1 reference

18 August 2017

page(s)

1197-1209

1 reference

Dose-dependent influence of didanosine on immune recovery in HIV-infected patients treated with tenofovir

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1197

Pancreatitis with didanosine and tenofovir disoproxil fumarate [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1197

Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1197

Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1197

Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1197

Early virologic failure in HIV-1 infected subjects on didanosine/tenofovir/efavirenz: 12-week results from a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1197

Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1197

Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1197

The safety and efficacy of adefovir dipivoxil in patients with advanced HIV disease: a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1197

Cidofovir-induced end-stage renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1197

Prediction of creatinine clearance from serum creatinine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1197

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1197

Renal safety of tenofovir in HIV treatment-experienced patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1197

Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1197

Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1197

Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1197

Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1197

Patterns of resistance emerging in HIV-1 from antiretroviral-experienced patients undergoing intensification therapy with tenofovir disoproxil fumarate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1197

The use of tenofovir disoproxil fumarate for the treatment of nucleoside-resistant HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1197

Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1197

Treatment of chronic hepatitis B in HIV-infected persons: thinking outside the black box.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1197

Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1197

Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1197

Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1197

Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1197

Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1197

Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1197

Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1197

Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1197

Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1197

10.1517/14656566.9.7.1197

21 January 2018

Identifiers

DOI

1 reference

18 August 2017

1 reference